DDIT3 and diffuse large B-cell lymphoma: Overall survival for patients with GCB and non‐GCB DLBCL was comparable in both the PV‐R‐CHP and R‐CHOP groups (PV‐R‐CHP, HR 1.30 [95% CI: 0.080–21.36]; p = 0.853, 1‐year OS: 94.7% and 90.0%; R‐CHOP, HR 2.00 [95% CI: 0.89–4.49]; p = 0.093, 1‐year OS: 82.2% and 76.1%) (Figure S4b).